Literature DB >> 15958455

New developments in the treatment of metastatic breast cancer: from chemotherapy to biological therapy.

G Mariani1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15958455     DOI： 10.1093/annonc/mdi719

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  6 in total

1.  The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials.

Authors:  Yuan Fang; Xinlan Qu; Boran Cheng; Yuanyuan Chen; Zhenmeng Wang; Fangfang Chen; Bin Xiong
Journal:  Tumour Biol       Date:  2014-11-12

2.  A phase II randomized study comparing navelbine and capecitabine (Navcap) followed either by Navcap or by weekly docetaxel in the first-line treatment of HER-2/neu negative metastatic breast cancer.

Authors:  M Ghosn; P Aftimos; F S Farhat; J G Kattan; C Hanna; N Haddad; F Nasr; G Chahine
Journal:  Med Oncol       Date:  2010-12-07       Impact factor: 3.064

3.  The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials.

Authors:  Xuan Wang; Chun Huang; Man Li; Yanjun Gu; Yanfen Cui; Yan Li
Journal:  Tumour Biol       Date:  2014-02-26

4.  A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines.

Authors:  George Orphanos; Athanasios Alexopoulos; Savvoula Malliou; George Ioannidis; Alexandros Ardavanis; Constantinos Kandylis; John Stavrakakis; Gerassimos Rigatos
Journal:  J Cancer Res Clin Oncol       Date:  2010-01       Impact factor: 4.553

5.  GSTT1, GSTP1, and GSTM1 genetic variants are associated with survival in previously untreated metastatic breast cancer.

Authors:  Jian Zhang; Ying Wu; Xichun Hu; Biyun Wang; Leiping Wang; Sheng Zhang; Jun Cao; Zhonghua Wang
Journal:  Oncotarget       Date:  2017-11-14

6.  The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer.

Authors:  Jian Zhang; Zhen Jia; Joseph Ragaz; Ying-Jian Zhang; Min Zhou; Yong-Ping Zhang; Gang Li; Bi-Yun Wang; Zhong-Hua Wang; Xi-Chun Hu
Journal:  BMC Cancer       Date:  2013-01-31       Impact factor: 4.430
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.